Para comunicar qualquer suspeita de reações adversas, deve contactar diretamente o INFARMED, I.P. ou o Titular de AIM através dos seguintes contactos:

INFARMED, I.P.:
Formulário online do Portal RAM disponível em:
http://www.infarmed.pt/web/infarmed/submissaoram (preferencialmente) ou:
INFARMED, I.P. - Direção de Gestão do Risco de Medicamentos
Parque da Saúde de Lisboa, Av. Brasil, 53 | 1749-004 Lisboa
Telefone: 21 798 73 73 e Linha do Medicamento: 800222444 (gratuita) | E-mail: farmacovigilancia@infarmed.pt

ou:

Bayer Portugal, Lda.
Avenida Vítor Figueiredo, nº4 – 4º piso | 2790-255 Carnaxide | Portugal | Telefone: 21 417 21 21 | Fax: 21 417 20 64 | E-mail: drugsafety.pt@bayer.com

ⁱ Van Den Eeden SK, Shan J, Bruce C, Glasser M. Ectopic pregnancy rate and treatment utilization in a large managed care organization. Obstet Gynecol. 2005 May;105(5 Pt 1):1052-7

ⁱⁱ Trabert B, Holt VL, Yu O, et al. Population-based ectopic pregnancy trends, 1993-2007. Am J Prev Med. 2011 May;40(5):556-60.

ⁱⁱⁱ Trabert B et al: Erratum on Trabert B et al, Population-based ectopic pregnancy trends, 1993-2007. Am J Prev Med 2012;42(1):107–108

^iv Torpy JM, Burke AE, Golub RM. JAMA patient page. Ectopic pregnancy. JAMA 2012;308:829.

^v NHS Choices, Symptoms of Ectopic Pregnancy, 2019. Available at https://www.nhs.uk/conditions/ectopic-pregnancy/symptoms/ (accessed 15 July 2019)

^vi Elson CJ, Salim R, Potdar N, Chetty M, Ross JA, Kirk EJ on behalf of the Royal College of Obstetricians and Gynaecologists. Diagnosis and management of ectopic pregnancy. BJOG 2016;.123:e15–e55

^vii Bouyer J, Coste J, Shojaei T et al. Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population based study in France. Am J Epidemiol 2003;157:185–194.

^viii Barnhart KT, Sammel MD, Gracia CR et al. Risk factors for ectopic pregnancy in women with symptomatic first-trimester pregnancies. Fertil Steril 2006;86:36–43.